ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Approves Large-Volume Processor For Cytyc’s ThinPrep Pap Test Samples.

June 30, 2000

DCT Announces Neutron Therapy RFP Available

January 19, 1979

NCI relaxes Core Grants Support For Clinical Trials Research

December 11, 1992

Cancer Leadership Council letter calls for permanent leadership of NCI and FDA.

November 23, 2005

Unclear Whether Insurance Will Cover AACR Losses

April 25, 2003

White House Okays Committee ‘Kill’ Lists; Workshops To Plan Projects In Carcinogenesis

July 22, 1977